A carregar...
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer
BACKGROUND: Studies have shown that antibodies targeting the intracellular (ICD) or extracellular domains (ECD) of human epidermal growth factor receptor 2 (HER2) are equivalent when traditional methods are used. We describe a new method to quantify ICD and ECD expression separately and assess the p...
Na minha lista:
| Publicado no: | J Natl Cancer Inst |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4554192/ https://ncbi.nlm.nih.gov/pubmed/25991002 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djv136 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|